Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
From BioCentury This Week · · 35 min
This plays from the publisher's own server. We do not host a copy.
Description
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury’s analysts assess what the deal does (https://www.biocentury.com/article/658506) for the Foster City, Calif.-based biotech’s pipeline. The analysts also discuss the case for using ctDNA (https://www.biocentury.com/article/658399) as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week’s PhRMA Forum, which focused on (https://www.biocentury.com/article/658494) China and the Trump administration’s most favored nation (MFN) drug pricing policy, and on the lessons (https://www.biocentury.com/article/658503) that can be drawn from FDA’s about-face on the recent vaccine application from Moderna.
View full story: https://www.biocentury.com/article/658516
#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA
00:00 - Introduction 02:34 - Gilead's Arcellx Buy 11:14 - ctDNA Surrogate Endpoints 21:59 - PhRMA Forum Takeaways 29:19 - FDA Moderna U-turn
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)